Abstract
Cardiovascular effects of cancer therapies are of concern. Prediction, diagnosis, and management of cardiotoxicity is a challenge. Cardiovascular biomarkers are being studied in relationship to cancer therapy, showing promise in detection and prevention of cardiotoxicity. We summarize the use of biomarkers in cardio-oncology and presents recommendations for their use. Troponins and natriuretic peptides are the most commonly used biomarkers. High-quality evidence supporting their use is lacking. Biomarkers can be incorporated into a detection strategy for cardiotoxicity. Large, well-powered studies are needed to delineate care strategies using biomarkers in the prediction and management of the cardiovascular effects of cancer therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 505-523 |
| Number of pages | 19 |
| Journal | Cardiology Clinics |
| Volume | 37 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 2019 |
| Externally published | Yes |
Keywords
- Anthracycline
- Biomarkers
- Brain natriuretic peptide
- Cancer
- Cardiotoxicity
- Chemotherapy
- Trastuzumab
- Troponin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine